ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
Pre-market 13:50:35 | |||
| 883.9 USD | -0.24% |
|
891.3 | +0.84% |
| 12:37pm | What other health conditions are weight-loss drugs being tested for? | RE |
| 12:36pm | Jefferies Adjusts Price Target on Eli Lilly to $1,015 From $994 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
883.9
USD
Average target price
856.2
USD
Spread / Average Target
-3.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.63% | 796B | |
| +40.71% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.25% | 244B | |
| +3.72% | 228B | |
| +12.75% | 214B | |
| +6.99% | 165B | |
| -3.65% | 157B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Goldman Sachs Raises Price Target on Eli Lilly to $723 From $650, Maintains Neutral Rating
